eligibility_summary
Inclusion: adults ≥18 with relapsed/refractory, measurable MM, ECOG 0–2, adequate organ/hematologic function. Exclusion: CNS MM, other plasma‑cell disorders (PCL, Waldenström, POEMS, amyloidosis) or nonsecretory MM, recent SCT (auto <3 m, allo <6 m or on immunosuppression), other cancer, autoimmune disease or recent immunosuppressants, acute infection/recent anti‑infectives, neuropathy ≥G2, HIV/HBV/HCV, active COVID‑19, allergy to CLN‑619/mAbs, pregnancy/breastfeeding or no contraception.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT06381141 evaluates CLN-619, a monoclonal antibody immunotherapy targeting MICA/MICB in relapsed/refractory multiple myeloma. Mechanism: CLN-619 binds MICA/MICB on tumor cells to enhance immune recognition, limit shedding of these stress ligands, and engage Fcγ receptors to promote antibody-dependent cell-mediated cytotoxicity/phagocytosis. Cells/pathways targeted: the MICA/MICB–NKG2D axis, activating NK cells and cytotoxic CD8+ T cells, innate effector functions via FcγR-bearing cells (NK cells, macrophages), reduction of soluble MICA/MICB that downregulate NKG2D. Phase 1b, dose-escalation, single-agent study.